


CURRICULUM VITAE



Name: Daniel W Rosenberg, PhD

Email: Rosenberg@uchc.edu

Phone: 860-679-8704

Fax: 860-679-7639

**Position: HealthNet Inc Chair in Cancer Biology and Professor of
Medicine**

Institution: University of Connecticut Health Center

Location: Farmington, CT, USA 06030-3101

Education:

| | | | |
|---------------------------------------|-----|------|----------------------------|
| SUNY, Buffalo, NY | BS | 1975 | Biochemistry |
| University of Michigan, Ann Arbor, MI | MS | 1978 | Toxicology/Environ Science |
| University of Michigan, Ann Arbor, MI | PhD | 1982 | Toxicology |

Representative Careers:

| Years | Position, Place |
|----------------|---|
| 1978 - 1982 | Guest Investigator, The Rockefeller University, New York, NY |
| 1982 - 1986 | Research Associate, The Rockefeller University, New York, NY |
| 1986 - 1987 | Experimental Toxicologist, Chevron Environmental Health Center, Inc., Richmond, CA |
| 1988 - 1991 | Assistant Professor, The Rockefeller University, New York, NY |
| 1991 - 1995 | Assistant Professor, Dept. Pharmaceutical Sciences, The University of Connecticut, Storrs, CT |
| 1996 - 2000 | Associate Professor, Dept. Pharmaceutical Sciences, The University of Connecticut, Storrs, CT |
| 2000 - 2004 | Associate Professor, School of Medicine and Dept. Genetics, UCH, Farmington, CT |
| 2004 - present | Professor, School of Medicine and Department of Genetics, UCH, Farmington, CT |
| 2004 - present | Director, Colon Cancer Prevention Program, UCH, Farmington, CT |
| 2013 - present | HealthNet, Inc., Endowed Chair in Cancer Biology, UCH, Farmington, CT |

Specialty & Present Interest:

Our laboratory focuses primarily on colon cancer prevention. We study early colon neoplasia in a large patient cohort and have established a large research repository of aberrant crypt foci and polyp samples. We also have developed a number of mouse cancer models that are used to better understand the role of prostaglandin signaling, oncogenic activation and cancer risk. Most recently we have begun to examine the influence of the gut microbiome on early colonic neoplasia and how plant-derived polyphenols may affect inflammatory signaling within the colonic mucosa.

Representative papers (up to 5):

1. Drew DA, Mo A, Grady JJ, Stevens RG, Levine J, Brenner B, Anderson JC, Farouhar FA, O'Brien MJ, Devers TJ and **Rosenberg DW**. 2018. Proximal aberrant crypt foci are associated with synchronous neoplasia and primed for neoplastic progression. *Molecular Cancer Research*, 16(3):486-95
2. Hanley MP, Hanh MA, Li AX, Wu X, Lin J, Wang J, Choi AH, Ouyang Z, Fong Y, Pfeifer GP, Devers TJ and **Rosenberg DW**. 2017. Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia. *Oncogene*, 36(35):5035-5044.
3. Mo A, Jackson S, Varma K, Carpino A, Giardina G, Devers TJ and **Rosenberg DW**. 2016. Epithelial-stromal interactions are altered at the earliest stages of colon cancer development. *Molecular Cancer Research*, 14(9):795-804.
4. Giardina C, Nakanishi M, Khan A, Xu W, Brenner B and **Rosenberg DW**. 2015. Regulation of VDR expression in *Apc*-Mutant mice, human colon cancers and adenomas. *Cancer Prevention Research*, 8(5):387-99 (article featured on front cover)
5. **Rosenberg DW**, Yang S, Pleau, DC, Greenspan E, Stevens RG, Rajan, TV, Heinen, CD, Levine, J and O'Brien M. 2007. Mutations in BRAF and KRAS differentially distinguish serrated vs. non-serrated hyperplastic aberrant crypt foci in humans. *Cancer Research*, 67:3551-3554 (*Priority Report*).